Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model

Journal of Neuroimmunology

Volumn 212, Issue 1-2, 2009, Pages 65-73

  Belmar, Nicole A ^a   Lombardo, John R ^a   Chao, Debra T ^a   Li, Olga ^a   Ma, Xiaohong ^a   Pong Afar, Melody ^a   Law, Debbie A ^a   Starling, Gary C ^a  

^a PDL BioPharma Inc   (United States)

Author keywords

Cerebrospinal fluid; Experimental autoimmune encephalomyelitis; Monoclonal antibody; T cell

Indexed keywords

CYCLOSPORIN A; N 297A; OKT 3; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; LYMPHOCYTE COUNT; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYMPTOMATOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; BLOOD-BRAIN BARRIER; CHEMOKINES; CYCLOSPORINE; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPINAL CORD; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 67650070278     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.04.022     Document Type: Article

References (44)

1. Abramowicz D., Schandene L., Goldman M., Crusiaux A., Vereerstraeten P., De Pauw L., Wybran J., Kinnaert P., Dupont E., and Toussaint C. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47 (1989) 606-608
2. Brown A., McFarlin D.E., and Raine C.S. Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab. Invest. 46 (1982) 171-185
3. Chao D.T., Ma X., Li O., Park H., and Law D. Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies. Immunol. Invest. 38 (2009) 76-92
4. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3 (2003) 123-132
5. Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis. Found. Symp. 252 (2003) 279-286 discussion 286-290
6. Chatenoud L., and Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7 (2007) 622-632
7. Chatenoud L., Baudrihaye M.F., Chkoff N., Kreis H., Goldstein G., and Bach J.F. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J. Immunol. 137 (1986) 830-838
8. Chatenoud L., Primo J., and Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158 (1997) 2947-2954
9. Chau L.A., Tso J.Y., Melrose J., and Madrenas J. HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Transplantation 71 (2001) 941-950
10. Compston A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
11. Cosimi A.B., Colvin R.B., Burton R.C., Rubin R.H., Goldstein G., Kung P.C., Hansen W.P., Delmonico F.L., and Russell P.S. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N. Engl. J. Med. 305 (1981) 308-314
12. Debure A., Chkoff N., Chatenoud L., Lacombe M., Campos H., Noel L.H., Goldstein G., Bach J.F., and Kreis H. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 45 (1988) 546-553
13. Fife B.T., Huffnagle G.B., Kuziel W.A., and Karpus W.J. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 192 (2000) 899-905
14. Friese M.A., and Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 128 (2005) 1747-1763
15. Glabinski A.R., Tani M., Strieter R.M., Tuohy V.K., and Ransohoff R.M. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol. 150 (1997) 617-630
16. Harjunpaa A., Wiklund T., Collan J., Janes R., Rosenberg J., Lee D., Grillo-Lopez A., and Meri S. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk. Lymphoma. 42 (2001) 731-738
17. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., and Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1692-1698
18. Herold K.C., Burton J.B., Francois F., Poumian-Ruiz E., Glandt M., and Bluestone J.A. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J. Clin. Invest. 111 (2003) 409-418
19. 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49 (1990) 1117-1123
20. 2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. Transplant. Proc. 23 (1991) 270-271
21. Hohlfeld R., and Wekerle H. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat. Clin. Pract. Neurol. 1 (2005) 34-44
22. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J.M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.F., Pipeleers D., and Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352 (2005) 2598-2608
23. Kohm A.P., Carpentier P.A., Anger H.A., and Miller S.D. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169 (2002) 4712-4716
24. Kohm A.P., Williams J.S., Bickford A.L., McMahon J.S., Chatenoud L., Bach J.F., Bluestone J.A., and Miller S.D. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174 (2005) 4525-4534
25. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., Backstrom B.T., Sobel R.A., Wucherpfennig K.W., Strom T.B., Oukka M., and Kuchroo V.K. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13 (2007) 423-431
26. Kuchroo V.K., Martin C.A., Greer J.M., Ju S.T., Sobel R.A., and Dorf M.E. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J. Immunol. 151 (1993) 4371-4382
27. Linthicum D.S., Munoz J.J., and Blaskett A. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell. Immunol. 73 (1982) 299-310
28. McGeachy M.J., and Anderton S.M. Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine 32 (2005) 81-84
29. McQualter J.L., Darwiche R., Ewing C., Onuki M., Kay T.W., Hamilton J.A., Reid H.H., and Bernard C.C. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 194 (2001) 873-882
30. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., and O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003) 15-23
31. Miyagishi R., Kikuchi S., Fukazawa T., and Tashiro K. Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J. Neurol. Sci. 129 (1995) 223-227
32. Murakami Y., Kong Y.Y., Nishimura Y., Nomoto K., Umesue M., Omoto K., Maeda T., and Nomoto K. Prevention of anti-T-cell receptor alpha beta monoclonal antibody-induced side-effects by treatment with cyclosporin A without interference of monoclonal antibody-induced immunosuppression in mice. Immunology 86 (1995) 238-243
33. Oliver A.R., Lyon G.M., and Ruddle N.H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J. Immunol. 171 (2003) 462-468
34. Paolillo A., Coles A.J., Molyneux P.D., Gawne-Cain M., MacManus D., Barker G.J., Compston D.A., and Miller D.H. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53 (1999) 751-757
35. Renders L., and Valerius T. Engineered CD3 antibodies for immunosuppression. Clin. Exp. Immunol. 133 (2003) 307-309
36. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2 (2002) 389-400
37. Sorensen T.L., and Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 57 (2001) 1371-1376
38. Steinman L. The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. Adv. Immunol. 49 (1991) 357-379
39. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., and Raine C.S. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 166 (2001) 7579-7587
40. Tischner D., Weishaupt A., van den Brandt J., Muller N., Beyersdorf N., Ip C.W., Toyka K.V., Hunig T., Gold R., Kerkau T., and Reichardt H.M. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 129 (2006) 2635-2647
41. Tran G.T., Carter N., He X.Y., Spicer T.S., Plain K.M., Nicolls M., Hall B.M., and Hodgkinson S.J. Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4. Int. Immunol. 13 (2001) 1109-1120
42. van Oosten B.W., Lai M., Hodgkinson S., Barkhof F., Miller D.H., Moseley I.F., Thompson A.J., Rudge P., McDougall A., McLeod J.G., Ader H.J., and Polman C.H. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49 (1997) 351-357
43. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., and Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356 (1992) 63-66
44. Yu P., Gregg R.K., Bell J.J., Ellis J.S., Divekar R., Lee H.H., Jain R., Waldner H., Hardaway J.C., Collins M., Kuchroo V.K., and Zaghouani H. Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J. Immunol. 174 (2005) 6772-6780